Gensight BiologicsLTS:0RIM -4.53% 9-Day RSI is 47.77 as of Jul. 12, 2026. The stock has 8 warning signs investors should review. Among 1,422 Biotechnology companies, Gensight Biologics ranks better than 50.84% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Gensight Biologics 9-Day RSI Related Terms
LTS:0RIM vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Gensight Biologics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (LTS:0RIM) has a 9-Day RSI of 47.77 as of Jul. 12, 2026. According to the industry distribution chart, Gensight Biologics ranks #699 out of 1422 companies in the Biotechnology industry, placing it in the top 49.2%.
Is Gensight Biologics' 9-Day RSI too high?
Gensight Biologics' current 9-Day RSI is 47.77. The Biotechnology industry median 9-Day RSI is 50.12. Gensight Biologics' value of 47.77 is 4.7% below this industry median. Based on the distribution chart, Gensight Biologics ranks #699 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint.
How does Gensight Biologics' 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #699 out of 1422 companies for 9-Day RSI. This puts Gensight Biologics in the upper half of its industry. The industry median 9-Day RSI is 50.12. Gensight Biologics' value of 47.77 is 4.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gensight Biologics's current 9-Day RSI of 47.77 is 4.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gensight Biologics's current 9-Day RSI is 47.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (LTS:0RIM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.08 — trading 105.3% above its estimated fair value. The current 9-Day RSI is 47.77 and 4.7% below the Biotechnology industry median of 50.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Gensight Biologics (LTS:0RIM), the current 9-Day RSI is 47.77 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RIM has been successfully added to your